Introduction
Chemokines are a large subfamily of chemoattractant cytokines which are classified into 4 highly conserved groups: CXC, CC, C and CX 3 C, based on the position of the first two cysteines adjacent to the amino terminus. The CXC chemokines act predominantly on neutrophils and T-lymphocytes, while the CC chemokines are active on various cell types, including monocytes and lymphocytes.
Chemokines selectively regulate the recruitment and trafficking of leukocyte subsets to inflammatory sites through chemoattraction and by activating leukocyte integrins to bind their adhesion receptors on endothelial cells (Ebnet and Vestweber, 1999) . Chemokines exert their effects by binding to seven transmembrane domain G protein-coupled receptors. Currently 11 receptors for the CC chemokines (CCR1-11) and six receptors for the CXC chemokines have been identified in man (Mackay, 2001) . Their ligands bind to the extracellular N-terminus, leading to phosphorylation of serine/ threonine residues on the cytoplasmic C-terminus, signalling and receptor desensitisation (Thelen, 2001) . There is apparent redundancy in the system; each receptor can respond to more than one chemokine; most chemokines can use more than one receptor and each leukocyte subset may express several receptors.
Recently there have been many reports of malignant cells expressing chemokine receptors and utilizing these to facilitate tumor cell survival, growth and movement. This review will describe the chemokine network in tumors, the expression of chemokine receptors by tumor cells and give mechanistic examples of how this large family of ligands and receptors can contribute to tumor cell spread.
Chemokine receptor expression profiles of cancer cells
The directed migration of tumor cells to distant organs via lymphatics and blood resembles chemokine-directed lymphocyte migration. Recent papers suggest that tumor cells may express restricted and specific patterns of chemokine receptors and that responses to chemokine gradients may contribute to metastatic spread. There is one chemokine receptor that appears to be expressed by a majority of cancer types, namely CXCR4, which is expressed by 23 different types of cancer, including cancers of epithelial, mesenchymal and haematopoeitic origin (Balkwill, 2004) . For example tumor cells from breast, prostate, pancreatic, lung and ovarian carcinomas, neuroblastoma and glioblastoma, all express CXCR4 (Koshiba et al., 2000; Rempel et al., 2000; Geminder et al., 2001; Muller et al., 2001; Scotton et al., 2001 , Schrader et al., 2002 Taichman et al., 2002; Burger et al., 2003; Hwang et al., 2003; Zeelenberg et al., 2003) . In other cancer cells studied, CXCR4 may be co-expressed with other CC or CXC chemokine receptors or less commonly, other receptors are present without expression of CXCR4. Human breast cancer cells express CXCR4 and CCR7 (Muller et al., 2001 ). Functional CCR7 is also found on gastric carcinoma cells (Mashino et al., 2002) and esophageal carcinoma (Ding Y et al., 2003) . Melanoma cells are reported to express CCR7 and CCR10 (Muller et al., 2001 ) and in another study to co-express CXCR4 and CXCR3 (Robledo et al., 2001 ). Leukaemic and lymphoma cells express a wider repertoire of chemokine receptors, probably reflecting their haematopoetic origin, adult T cell leukaemia/lymphoma (ATLL) cells frequently express CCR4 (Ishida et al., 2003) , cutaneous T cell lymphoma (CTCL) cells express functional CCR3 (Kleinhans et al., 2003) and B cell lymphomas are reported to express CXCR3 and CXCR5 (Jones et al., 2000) .
CXCR4 and CXCL12 in normal development
Below we will describe how the repertoire of chemokine receptors on different tumor types may be related to patterns of spread.
It must be noted that CXCR4 is not a tumor specific marker and not all cancers express this receptor. Furthermore, both receptor and ligand, CXCL12 (previously SDF1-α), are widely expressed in normal tissues and play a critical role in fetal development, mobilization of haemopoietic stem cells and trafficking of naïve lymphocytes (Rossi and Zlotnik, 2000) . Despite the apparent redundancy within the chemokine system this particular pair are mutually exclusive, CXCR4 is the only receptor for CXCL12 and cannot bind any other ligand. The importance of this interaction is highlighted by the fact that deletion of either CXCR4 or CXCL12 is embryonic lethal. Mice lacking either this ligand or receptor do not develop normally after E13. Defects can be found in the haematopoietic system, heart, cerebellum and vasculature (Zou et al., 1998) and (Tachibana et al., 1998) . The critical role for CXCR4 in embryogenesis has been studied in zebrafish where formation of the mechanosensory posterior lateral line and migration of primordial germ cells (PGC) is controlled by CXCR4 expressing cells which respond to a CXCL12-like molecule (David et al., 2002) and (Doitsidou et al., 2002) . Migration of PGC in fish and murine embryos is also controlled via CXCR4-CXCL12 interactions, deletion or inhibition of CXCR4 or CXCL12 results in reduced migration and ectopic location of PGCs (Ara et al., 2003; Knaut et al., 2003) .
Within primary tumors of the ovary (and possibly other primary cancers) only a sub-population of malignant cells express CXCR4 (1 -20% in the case of ovarian cancer express CXCR4) (Scotton et al., 2001) . Furthermore, when non small cell lung cancer cells (NSCLC) are grown in SCID mice only 35% cells in the primary tumor express CXCR4 compared with 99% of cells in metastases (Balkwill, 2004) . With the knowledge of the role of CXCR4 in stem cell biology (Youn et al., 2000) and the current interest in cancer stem cells (Singh et al., 2003) these observations raise the intriguing possibility that CXCR4 may be a marker for cancer stem cells. Further investigation is needed to determine whether the CXCR4 expressing sub-population within a primary tumor are those that migrate and survive to form metastatic deposits.
Chemokine expression in the tumor microenvironment
Within most cancers there is an extensive network of chemokines and chemokine receptors (Vicari and Caux, 2002) (Balkwill and Mantovani, 2001) , often tumor production of chemokines is disregulated and receptor expression and signalling may be abnormal (Dhawan and Richmond, 2002; . Solid tumors comprise a mixture of malignant and host stromal cells. Initially, stromal cells have to be recruited into the tumor tissue by the cancer cells and although there are some reports of infiltrating immune cells controlling tumor growth (Zhang et al., 2003) , it is possibly more likely that a tumor attracts stromal cells which are advantageous for tumor growth. For example, infiltrating macrophages produce growth factors, angiogenic factors, inflammatory cytokines and chemokines (Balkwill and Mantovani, 2001 ). CCL2 stimulation of monocytes promoted tumor formation of melanoma cells (Nesbit et al., 2001) . CD4 + T cells were reported to enhance invasion and disease progression in an experimental model of skin carcinogenesis (Daniel et al., 2003) .
The composition of the leukocyte infiltrate in many carcinomas is related, in particular, to tumor and stromal cell production of CC chemokines (Balkwill and Mantovani, 2001 ). There are limited examples of tumors where the complex chemokine network has been fully characterised and then related to infiltrating leukocytes. Examples include Hodgkin's disease which expresses CCL17 (TARC), CCL11 (eotaxin), CCL22 (MDC) that attract Th2 lymphocytes and the Th1-attracting chemokines CXCL10 (IP-10), CXCL9 (Mig-1), CCL2 (MCP-1), CCL3 (MIP-1α), CCL5 (RANTES) and CXCL1 (GROα) . Ovarian cancer is characterised by the presence of infiltrating macrophages and CD8 + T lymphocytes. CCL2 localised to epithelial areas of the tumor and correlated with the extent of lymphocyte and macrophage infiltration (Negus et al., 1995; Negus et al., 1997) . CCL3, CCL4 (MIP-1β) and CCL5 were also present in solid ovarian tumors and localised to tumor infiltrating leukocytes. CCL5 expression also correlated with the extent of the CD8 + T lymphocyte infiltrate (Negus et al., 1997) . In ovarian cancer ascites, mRNA and pico to nanomolar levels of protein for CCL2, CCL3, CCL4, CCL5, CCL8 (MCP-2) and CCL22 were detected. Variable numbers of macrophages and CD3 + T lymphocytes (predominantly CD4 + ) were present in ascites and a direct correlation between CCL5 concentration in ascitic fluid and infiltrating CD3 + T cells was reported (Milliken et al., 2002) . Breast cancer cells have been reported to produce CCL2 and CCL5 and there is a positive correlation between macrophages, lymph node metastasis and clinical aggressiveness (Luboshits et al., 1999; Saji et al., 2001 ).
CCL5 levels correlated with breast cancer progression whereas benign breast disease had minimal chemokine expression (Azenshtein et al., 2002) . In esophageal squamous cell carcinomas CCL2 expression was significantly associated with the extent of macrophage infiltration, tumor cell invasion and tumor vascularity . In an experimental murine breast cancer model, overexpression of the cytokine CSF-1 (M-CSF) increased infiltration of macrophages and accelerated tumor growth, invasion and metastasis (Lin et al., 2001 ).
However, there are conflicting data on the association of CCL2 and CCL5 expression, the extent of the leukocyte infiltrate and tumor progression. For instance, high serum levels of CCL2 in pancreatic cancer patients correlated with the extent of macrophage infiltration into the tumor but was associated with good patient prognosis (Monti et al., 2003) . Likewise, CCL5 expression by tumor cells in NSCLC patients was associated with an 'active lymphocyte response' and was a positive predictor of survival (Moran et al., 2002) . needs to be established and in breast, prostate and ovarian cancer, neuroblastoma, melanoma and some forms of leukaemia, the respective ligand is strongly expressed at sites of tumor spread. Melanoma cells express functional CCR7 and CCR10 and high expression of ligands for these receptors are reported at the two major sites of metastasis, skin and lymph nodes (Muller et al., 2001 ). CCR7 and CXCR4 are found on human breast cancer cells and the ligand for CCR7, CCL21, (SLC) is highly expressed in lymph nodes and strong expression of the CXCL12 was reported in the target organs for breast cancer metastases (Muller et al., 2001 ).
Moreover, breast cancer cells migrated towards tissue extracts from these target organs and chemotaxis could be partially abrogated by neutralising antibodies to CXCR4 (Muller et al., 2001 ).
Data from 600 prostate cancer patients revealed that CXCR4 protein expression was significantly elevated in localised and metastatic prostate cancer compared to normal or benign prostate tissue and CXCL12 protein levels were higher in metastatic, compared to normal, prostate tissue (Sun et al., 2003) . Expression of CCR7 by gastric cancer cell lines results in directed migration in vitro (Mashino et al., 2002) . Studies using clinical biopsies suggested that the most important factor determining lymph node metastasis in gastric cancer was CCR7 expression in the primary tumor as there was a significant difference in both lymph node metastasis and lymphatic invasion between CCR7 positive and negative cases. CCR7 expression was also reported in chronic lymphocytic leukaemia (CLL) and the specific ligands, CCL21 and CCL19, were located in high endothelial venules (Till et al., 2002) . Two chemokine receptors, CCR3 and CCR4 have been implicated in skin homing of lymphoma cells. In CTCL, CCR3 and CCL11 were detected in tumor cells in skin lesions (Kleinhans et al., 2003) .
Whereas expression of CCL17 by cutaneous endothelia results in accumulation of CCR4 expressing ATLL cells in the skin (Ishida et al., 2003) . CCR4 was significantly associated with skin involvement in this disease and was an unfavourable prognostic factor (Ishida et al., 2003) .
Experimental murine cancer models provide some experimental proof that cancer cells may harness chemokine-directed trafficking mechanisms to home to specific sites. When the chemokine receptor CCR7 was introduced into B16 melanoma cells metastasis to lymph nodes was increased (Wiley et al., 2001) . However, when the same cells were transfected CXCR4 spread to the lymph nodes was rare but B16-CXCR4 had a marked increase in the ability to form lung metastases (Murakami et al., 2002) . In most in vitro studies with CXCR4 expressing cancer cell lines, activation of the receptor with CXCL12 stimulates specific migration of cancer cells or invasion through matrigel or through monolayers of endothelial cells, fibroblasts or bone marrow stromal cells (Koshiba et al., 2000; Geminder et al., 2001; Scotton et al., 2001; Scotton et al., 2002; Hwang et al., 2003) . However, we feel that this may be an oversimplification, that tumor cell expression of CXCR4 is not simply a migrational cue. It is clear that the tumor microenvironment contains an extensive and varied mix of chemokines, both CC and CXC chemokines and that this 'network' may control the leukocyte infiltrate into the tumor (Fig. 1A) . In the following section we will discuss whether similar chemokine-receptor networks can control tumor cell movement out of a cancerous tissue.
Chemokine gradients and the spread of malignant cells
Chemokines control the directional migration of leukocytes and it seems that mechanisms utilised for leukocyte trafficking may also used by tumor cells (Fig. 1B) . We described in section 3, how certain cancer cells can have restricted and specific expression of chemokine receptors, in particular CXCR4 and CCR7 and this may be one factor in the development of site specific metastasis. For chemokine receptor expression by a cancer cell to be advantageous a chemokine gradient is required/
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Many studies have not examined the expression of CXCL12 in malignant tissue, although it is found in primary tumor sites in lymphoma, glioma, ovarian and pancreatic cancer, but, in other cancers, such as breast, thyroid, neuroblastoma and certain haematological cancers, CXCL12 is found at sites of metastasis (Balkwill, 2004) . CXCL12 expression varies with individual cancer types in patterns that could be consistent with attraction of cancer cells to distant sites, or, conversely, to retention of cells in the primary tumor. A similar contradiction is apparent in vitro, CXCR4 expressing breast and ovarian cancer cell lines do not express CXCL12 although glioma, prostate and pancreatic cancer cell lines do express this ligand. Indeed, our work with ovarian cancer demonstrated that nanogram quantities of CXCL12 were present in ascitic fluid and CXCR4 was expressed more strongly expressed by tumor cells in ascites. Our initial conclusion was that this chemokine receptor/ligand interaction could be involved in peritoneal spread of this cancer (Scotton et al., 2001) . However, we then found that CXCL12, was also strongly expressed by tumor cells in the solid ovarian cancer biopsies and had many more functions beside stimulating migration. Thus far, the significance of high levels of tumor-derived CXCL12 at the site of the primary lesion is not fully understood. However, the process of metastasis is complex multi-step process and there are several stages at which the interaction between tumor cell chemokine receptors and their ligands could be important. We will discuss evidence to suggest that, in addition to tumor cell movement to a gradient, chemokines play a role in tumor cell adhesion, invasion, survival, growth and angiogenesis.
Intracellular signaling pathways activated by chemokine receptors on mailgnant cells
All chemokine receptors are seven transmembrane domain receptors; signal transduction through these leads to activation of G proteins and phospholipase C and the elevation of cytosolic free calcium (Thelen, 2001) . Stimulation of chemokine receptors also results in activation of ERK-2 and PI 3-kinase leading to formation of PIP3 and activation of PKB/Akt. In contrast to other chemokine receptors, stimulation of CXCR4 can lead to prolonged activation of these two signaling pathways (Tilton et al., 2000) . Signaling via CXCR4 also enhances tyrosine phosphorylation, association of components of focal adhesion complexes such as paxillin and NFkB activity in nuclear extracts (Ganju et al., 1998) .
There is one interesting report of cross talk between the BCR/ ABL oncogenic tyrosine kinase and CXCR4 signalling (Ptasznik et al., 2002) . In CML, BCR/ABL kinase phosphorylates, activates and disregulates proliferation and survival pathways of progenitor cells in the bone marrow. Immature leukaemic cells leave the marrow and are found in large numbers in the blood and spleen. BCR/ABL strongly activates a CXCR4-dependent signalling component through the Src family tyrosine kinase, Lyn. Cross talk between BCR/ABL and CXCR4 signalling may allow the oncoprotein to couple to PI3-kinase and MAPK cascades and 'take over' the chemokine pathway. This could lead to disruption of chemotaxis and hence release of the transformed cells into the periphery.
In a metastatic breast cancer cell line, NF-κB directly regulates the CXCR4 promoter and can upregulate expression of CXCR4, facilitating increased responses to CXCL12 (Helbig et al., 2003) .
Also in breast cancer lines, CXCL12 also induces phosphorylation of the molecules FAK, Pyk2, the cytoskeletal proteins paxillin and Crk, the tyrosine phosphatase SHP2 and the adaptor protein Cbl (Fernandis et al., 2004) .
Chemokines, integrins, adhesion and invasion
Signalling via chemokine receptors can modulate tumor cell expression of integrins which can then facilitate adhesion of cancer cells to and/or invasion through the extracellular matrix (Fig. 1B) . Work in our laboratory, has demonstrated that CXCL12 stimulation of different ovarian cancer cell lines upregulates the expression of β1 integrin (Scotton et al., 2001 ) and this integrin modulation correlates with increased tumor cell adhesion to fibronectin (Kulbe et al., manuscript in preparation). Ovarian cancer cell lines invade through matrigel to CXCL12 and this is abrogated by the broad spectrum matrix metalloprotease (MMP) inhibitor marimistat . β1 integrins have also been reported to regulate both the formation of and adhesion within, ovarian cancer spheroids (Casey and Skubitz, 2000) . In small cell lung cancer cells (SCLC) CXCL12 stimulation induced firm adhesion to marrow stromal cells via activation of α4β1 integrin and also induced SCLC cell invasion into the extracellular matrix (Burger et al., 2003) .
Overexpression of the signalling molecule Akt2 in both breast and ovarian cancer cell lines resulted in cell lines which exhibited increased adhesion to and invasion through collagen IV due to upregulation of β1 integrins and these cell lines were also more metastatic than control lines in vivo (Arboleda et al., 2003) . In lymphocytes, the chemokines CXCL12 and CCL21 activate adhesion, mediated by LFA-1 and VLA-4, and also transendothelial migration where the small GTPase, RAP1, serves to increase the adhesive capacity of these adhesion molecules (Shimonaka et al., 2003) . In both normal and transformed lymphocytes CXCL12 augments α4β7 mediated adhesion via activation of the small GTPase RhoA (Wright et al., 2002) . Adhesion mechanisms can also impact on chemokine receptor expression, e.g. in non-transformed lymphocytes, activation of L-selectin (by antibody crosslinking or specific ligands) mobilises intracellular stores of CXCR4 to increase cell surface expression (Ding Z et al., 2003) . It would be interesting to also investigate these interactions of chemokines and adhesion on tumor cells under flow conditions.
In the B16 melanoma experimental metastasis model, CXCR4 transfected cells show enhanced adhesion to dermal and pulmonary microvascular endothelial cells (Murakami et al., 2002) .
Under flow conditions, these transfected cell lines showed no evidence of rolling before arrest and adhesion was dependent on β1 integrin expression and adhesion of transfectants to endothelial cells both in vitro and in vivo was inhibited by anti-β1 antibodies (Cardones et al., 2003) . Unpublished data from our laboratory suggest that transfection of ovarian cancer cells with CXCR4 results in a concomitant upregulation of various α and β integrin subunits including αv (Kulbe et al., manuscript in preparation).
Data from the study of metastatic breast cancer cells suggest that the expression of αvβ3 integrin strongly promotes breast cancer metastasis via a mechanism where αvβ3 cooperates with MMP-9 to facilitate migration (Rolli et al., 2003) .
Growth / survival of tumor cells by chemokines
Deregulated chemokine production by tumors may contribute directly to transformation of tumor cells by acting as growth and survival factors, in an autocrine and/or paracrine manner (Fig. 1C) . Melanoma cells express elevated levels of the CXCR2 receptor and also constitutively produce CXCL1 and CXCL8 (IL-8) allowing autocrine stimulation by these chemokines which enhances survival, proliferation and tumor cell migration (Schadendorf et al., 1993; Luan et al., 1997; Dhawan and Richmond, 2002) . The chemokines CXCL1 and CXCL8 also stimulate growth of pancreatic tumor cell lines (Takamori et al., 2000) . Pancreatic cancer samples also express CCR6 and proliferate in response to the CC chemokine CCL20 (MIP-3α) (Kleeff et al., 1999) .
In many cancers interactions between CXCL12 and CXCR4 stimulate proliferation. Examples include, prostate cancer cells (Sun et al., 2003) , glioblastoma cells (Zhou et al., 2002; Barbero et al., 2003) and malignant plasma cells of multiple myeloma (Hideshima et al., 2002) .
In other cancers, CXCL12 can also stimulate cancer cell proliferation or survival under suboptimal conditions e.g. epithelial ovarian cancer where CXCL12 stimulation enhances tumor cell proliferation in low serum conditions .
The CXCR4-CXCL12 interaction and downstream signalling, often partially regulated by phosphorylation of Akt, may promote growth/survival of tumor cells to allow cells to grow in distant and less favourable sites (Kikima et al., 2002; Schrader et al., 2002; Zhou et al., 2002; Barbero et al., 2003; Sun et al., 2003) .
Role of chemokines in malignant progression
Chemokines may also regulate angiogenesis within both the primary tumor and metastatic deposits (Fig. 1C) . CXC chemokines containing the 3 amino acid (ELR) motif glutamine-leucine-arginine, such as CXCL8, CXCL1, CXCL5 (ENA-78), CXCL6 (GCP-2) and CXCL7 (NAP-2), promote angiogenesis whereas those lacking this motif, such as CXCL9 and CXCL10 (IP-10), are often antiangiogenic (Belperio et al., 2000) . Examples include, levels of CXCL10 in human lung cancers which were inversely related to tumor progression (Belperio et al., 2000) and elevated levels of CXCL5 which were found in NSCLC and correlated with the vascularity of the tumors and angiogenesis (Arenberg et al., 1998 ).
An elegant study demonstrated that CXCR4 surface expression could be prevented by transfecting cell lines with a CXCL12 construct containing an endoplasmic reticulum (ER) retention sequence, this binds CXCR4 in the ER retains it there (Zeelenberg et al., 2001 ). When T cell hybridoma cells were transfected with this construct and injected i.v. there was a reduction in the number of metastases to distant organs (Zeelenberg et al., 2001) . Transfection of colorectal tumor cells with this construct again resulted in reduced metastasis to lungs and liver. However, closer investigation revealed that these cells colonised the lungs to a similar extent as the parental cells but these micrometastases, although they survive, fail to proliferate (Zeelenberg et al., 2003) . Unpublished work from our laboratory has also shown a role for CXCR4 in malignant progression, over expression of CXCR4 in ovarian cancer cells leads to increased migration, invasion, adhesion and survival in response to CXCL12 in vitro. When grown intraperitoneally in nude mice, the CXCR4 transfected cells are able to establish extensive metastases outside the peritoneum unlike parental cells (Kulbe et al., manuscript in preparation). Furthermore, when subpopulations of breast cancer cells with enhanced metastatic abilities were isolated by in vivo selection, gene expression profiles detected four highly over expressed genes: CXCR4, IL-11, osteopontin and connective tissue-derived growth factor, CTGF. Transfection studies demonstrated that CXCR4 causes a limited but significant increase in bone metastases but triple transfectants with IL-11, osteopontin and CXCR4 or CTGF show a dramatic increase in both the rate and incidence of bone metastases (Kang et al., 2003) .
CXCR4 expression and action may be linked to other factors that are involved in the processes of malignancy. CXCL12 stimulation of ovarian cancer cell lines and primary cells isolated from ascitic disease caused production of the pro-inflammatory cytokine TNF-α . Production of TNF-α in this disease has been implicated in tumor/stromal communication and tumor progression (Szlosarek and Balkwill, 2003) . There are also links between CXCR4 and vascular endothelial growth factor (VEGF). In breast cancer cell lines, VEGF was demonstrated to have an autocrine action and induce expression of CXCR4 expression which promoted migration/invasion towards CXCL12 (Bachelder et al., 2002) . VEGF and basic fibroblast growth factor also induce expression of CXCR4 on human endothelial cells (Salcedo et al., 1999) which again highlights the reciprocal links between chemokines and angiogenic factors.
Hormones have also been linked with chemokine action which maybe particularly relevant in gynaecological cancers. It was reported that CXCL12 is a target of estrogen action in estrogen receptor-alpha positive human ovarian and breast cancer cell lines (Hall and Korach, 2003) . Estradiol treatment induces expression of CXCL12 by estrogen receptor+ cell lines and promotes cell proliferation, proliferation can be blocked with either addition of anti-CXCL12 antibody or ER antagonists demonstrating another chemokine-mediated paracrine pathway to promote cancer cell proliferation. Regions of hypoxia are common in solid tumours due to the chaotic and intermittent blood supply and the high metabolic rate of tumour cells (Vaupel et al., 1998) . Two recent studies have demonstrated an interaction between hypoxia and CXCR4 expression. (Schioppa et al., 2003) demonstrated that low levels of oxygen induce high expression of CXCR4 on monocytes, macrophages, endothelial cells and tumor cells. Hypoxia inducible factor-1α (Hif-1α) activation is involved in CXCR4 upregulation, as is an increase in the stability of CXCR4 mRNA (Schioppa et al., 2003) . Under normoxic conditions the von Hippel-Lindau tumor suppresser protein (pVHL) negatively regulates CXCR4 expression as it targets HIF-1α for degradation, however under hypoxic conditions this program is suppressed which results in HIF-1α-dependent CXCR4 upregulation. These results suggest the first mechanism of how CXCR4 becomes expressed by tumor cells and also how it could confer a survival advantage to the cells that acquire such expression (Staller et al., 2003) . A study of mutations of the VHL gene in renal cell carcinoma revealed that mutations are associated with high CXCR4 expression and poor patient prognosis (Staller et al., 2003) .
Concluding remarks
Recent studies have demonstrated that chemokine-receptor interactions, in particular those relating to CXCR4-CXCL12, can impact at any stage of tumor biology from tumor development to stimulation of cell movement, adhesion, invasion, proliferation and malignant progression.
